Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...

Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated antibodies for rare cell and ...

The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing Bio-Rad experts Eddy van ...

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations,... Bio-Rad Labs’s revenue forecast is 696.62M. How Did Bio-Rad Labs ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the Vericheck ddPCR™ Empty-Full Capsid Kit ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and ...